LILLY's PROZAC FOR OBSESSIVE-COMPULSIVE DISORDER
LILLY's PROZAC FOR OBSESSIVE-COMPULSIVE DISORDER approved Feb. 28 with the conditions that Lilly conduct a relapse prevention trial and a pediatric OCD study and enhance certain sections of the adverse reaction section of labeling. The serotonin reuptake inhibitor fluoxetine has been approved since 1987 for the treatment of depression. The second indication is for the "treatment of obsessions and compulsions" in patients with OCD who have obsessions or compulsions that "cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth